The Quantellect read.As of Nov 19, 2026, 9 active firms cover Oruka Therapeutics, Inc: 9 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $100.00 to $200.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $149.33 sits 56% above the current $95.75. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.73 next quarter toward $-2.86 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy9100%
Neutral00%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$149.33
+56.0% upside
Average target across 6 active firms as of Nov 19, 2026 vs $95.75 current
Highest Target$200.00
Average Target$149.33
Lowest Target$100.00
Detailed analyst forecasts for ORKA
Showing 1–6 of 6 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 9 of 9 active firms rate ORKA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ORKA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.73
Range $-0.88 – $-0.60 · 5 analysts · +52% YoY
Next period, 5 analysts expect Oruka Therapeutics, Inc. to earn $-0.73 a share (range $-0.88 – $-0.60), versus $-0.48 a year earlier. Full-year consensus is $-2.57, growing to $-2.86 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Oruka Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ORKA.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$165.00+72.3% to target
Overall win rate
48%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #84
Buy
$200.00+108.9% to target
Overall win rate
50%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$133.00+38.9% to target
Overall win rate
43%
+ Follow
#4
Julian Harrison
BTIG · Rank #183
Buy
$151.00+57.7% to target
Overall win rate
41%
+ Follow
#5
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$120.00+25.3% to target
Overall win rate
33%
+ Follow
ORKA stock forecast FAQ
What is ORKA's average 12-month price target?+
The 6 active firms with a live target average $149.33 for Oruka Therapeutics, Inc. over the next 12 months, ranging from a $200.00 high to a $100.00 low, as of Nov 19, 2026.
Is ORKA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ORKA?+
The Street-high target is $200.00 (Guggenheim), and the Street-low is $100.00 (UBS). The average of all 6 active-firm targets is $149.33.
How many active Wall Street firms cover ORKA?+
9 active firms have a recognized rating on Oruka Therapeutics, Inc. as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ORKA?+
Among analysts who currently cover ORKA, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $165.00 target.
What is Oruka Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.73 per share (range $-0.88 – $-0.60) across 5 analysts. Full-year EPS is projected at $-2.57, rising to $-2.86 the following year.
How much revenue is Oruka Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ORKA lately?+
As of Nov 19, 2026, 9 of 9 active firms rate ORKA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ORKA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.